#1NATCO PHARMA LIMITED INVESTOR PRESENTATION Quarter I ending June 30 FY 2023-24 NATCO 1#2DISCLAIMER/IMPORTANT DISCLOSURE NATCO THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE "COMPANY"). The material that follows is a Presentation of general background information about the Company's activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares. This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward- looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company's intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company's actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment and business income (vi) cash flow projections etc. (vii) exposure to market as well as other risks. The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements based on any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates. Any opinions expressed in this presentation are subject to change without notice. The presentation should not be construed as legal, tax, investment or other advice. None of the Company or any of its affiliates, advisers or representatives accepts any liability whatsoever for any loss howsoever arising from any information presented or contained in this presentation. The information contained in this presentation has not been independently verified. Furthermore, no person is authorized to give any information or make any representation which is not contained in, or is inconsistent with, this presentation. Any such extraneous or inconsistent information or representation, if given or made, should not be relied upon as having been authorized by or on behalf of the Company. Further, past performance is not necessarily indicative of future results. This document is just a Presentation for information purposes and private circulation only and is not intended to be a "prospectus" or "offer document" or a "private placement offer letter" (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the equity shares of the Company or any of its subsidiaries. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company's securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from. This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This presentation is confidential and this presentation or any part thereof should not be used or relied upon by any other party or for any other purpose and should not be copied, reproduced, recirculated, redistributed, published in any media, website or otherwise, in any form or manner, in part or as a whole, without the express consent in writing of the Company. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited. The distribution of this presentation in certain jurisdictions may be restricted by law. Accordingly, any persons in possession of the aforesaid should inform themselves about and observe any such restrictions. 2#3KEY HIGHLIGHTS Diversified enterprise focused in pharmaceutical sector with presence across geographies - India, US and ROW. Strong brand position in domestic pharma segments • Well established player in oncology with brands catering to diseases including breast, bone, lung and ovarian cancer • Expanding reach to wider pool of doctors through NATCO REACH Focused on complex generics for the US Markets with niche Para IV and Para III filings . Established front-end presence through Dash acquisition. Two R&D centers with around 465 employees (1) Targeting growth in Crop Health Sciences business with state-of-the-art manufacturing facilities for both technical and formulation Total revenues (2) of 28,117 million for the financial year ended 31st March 2023 Listed on BSE and NSE with a market capitalisation (3) of USD 1.51 billion Incorporated in 1981 and headquartered in Hyderabad with around 4,900 employees across all locations (1) (1) As of March 31, 2023 (2) Represents consolidated revenue (3) Market capitalization as of June 30, 2023 using INR / USD exchange rate of *82.0428 NATCO 3#4PERFORMANCE AT A GLANCE Financial Performance (¹) (million) 1400 1200 1000 800 600 400 200 28,117 43.2% 41.6% 22,424 22,247 21,557 20,224 20,438 9,688 9,250 6,962 6,444 6,900 4,608 LLL 7,098 4,409 3,625 1,700 10,402 7,153 0 02-Jul-18 FY 2018 FY 2019 FY 2020 FY 2021 Revenue EBITDA ■PAT NATCO Pharma Stock Performance 02-Jul-19 02-Jul-20 FY numbers have been prepared under Ind AS (1) Represents consolidated gross revenue and includes other income (3)As on June 30,, 2023 02-Jul-21 02-Jul-22 (2) Represents PAT after minority interest FY 2022 Profitability Margins NATCO 34.1% 32.9% 31.0% 29.0% 22.8% 20.5% 17.7% 8.3% 37.0% 25.4% FY 2023 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 EBITDA% PAT% Ownership Structure (3) 50.24% 49.76% 29% 24% 23% 18% Efficiency Ratios 15% 14% 12% 11% 5% 4% 18% 15% ■ Promoter Public FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 No. of fully paid up equity shares held: 17,91,09,870 ROE ROCE 4#5KEY BUSINESS SEGMENTS DOMESTIC FORMULATIONS EXPORT FORMULATIONS SUBSIDIARIES NATCO API BUSINESS Overview(1) • Three key business segments: Oncology, Specialty Pharma, Cardiology and Diabetology Strong brand position in the domestic oncology Specialist sales force of nearly 550 personnel and ~1,000 distributors Strengthened C&D portfolio through additional 250+ sales force Launched 11 new products across oncology and C&D Targeting 20 product launches a year with over 12% growth Strengthening the gastroenterology, critical care, oncology and cardio-diabetes portfolios with expanded geographical, disease and therapy area coverage Focused on niche opportunities in the US, Canada and emerging markets Integration of Dash Pharmaceuticals LLC complete and name changed to Natco Pharma USA LLC Focus on Para IV and First-to-File molecules Strengthening presence in South-east Asia, MENA and LATAM among other ROW markets by registering our niche product portfolio in these countries • • Operations in Brazil, Canada, Singapore, Australia and Philippines generic Amongst top 10 companies by sales revenue in Canada. Strong portfolio of Oncology, cardiovascular and CNS therapies In Brazil, continued to increase our presence in the Oncology and primary healthcare segments with strong market share in Everolimus and Apixaban Building a strong product portfolio in Singapore in both Tender and Private segments 44 active DMFs (1) in the US with niche products under development Exports focused on US, Europe and emerging markets Oncology APIs and specialty products Difficult-to-make chemistry with long synthesis. Expanding our oligonucleotide portfolio 1.As of March 31, 2023 5#6US MARKET FOCUS- COMPLEX GENERICS & FRONTEND Predominantly focused on high-barrier-to-entry products that are typically characterized by one or more of the following: Challenging delivery systems Intricate Chemistry ◉ Difficult or complex manufacturing process Will continue to work with partners for complex products or those involving unique patent challenges Low risk business model; through partnerships with global pharmaceutical players ■ Marketing partner typically responsible for litigation and regulatory process to secure ANDA approval. Multi-site approvals ☐ Multi-sourcing arrangements Launched Ondansetron and Nitroglycerin through NATCO Pharma USA LLC; Armodafinil to be launched soon PIPELINE OF NICHE IN THE US Revlimid Key Brand Copaxone Tamiflu KEY PRODUCTS IN THE PORTFOLIO (1) Afinitor(2.5 mg, 5 mg, 7.5 mg and 10 mg) Fosrenol Doxil Tykerb Zortress Molecule Lenalidomide Glatiramer Acetate Oseltamivir Everolimus (higher strength) Lanthanum Carbonate Liposomal Doxorubicin Lapatinib Ditosylate Everolimus (lower strength) NATCO Therapeutic Segment / Primary Indication Cancer/Multiple Myeloma CNS/Multiple Sclerosis Anti-Viral/Influenza Cancer/Breast Renal disease Cancer/Ovarian and other Cancer/Breast Immunosupressant/Organ Transplant 19 Para IVs in the pipeline (2) Of which 7 are approved (2) (either tentative or fully) Key Brand SOLO FIRST TO FILE IN THE PIPELINE (1) Eliquis Key Brand Molecule Therapeutic Segment / Primary Indication Ozempic Lynparza Tracleer Kyprolis Imbruvica Zydelig Bosentan (32mg) Anti-hypertensive Kyprolis Carfilzomib (10mg) Cancer/Multiple Myeloma Ibrutinib (tablet) Cancer/Leukaemia Pomalyst Idelalisib Cancer Lonsurf Lynparza Olaparib Ovarian/Breast Cancer Ozempic Balversa Semaglutide pen (8mg/3ml) Erdafitinib Diabetes Yondelis Trabectedin Bladder Cancer Calquence Zydelig Idelalisib Imbruvica Carfilzomib Ibrutinib Pomalidomide Trifluridine/Tipracil Acalabrutinib Ovarian/Breast Cancer Cancer/Multiple Myeloma Cancer/Leukaemia Cancer/Multiple Myeloma Metastatic colorectal cancer Advanced soft-tissue sarcoma/ ovarian cancer Cancer/Blood Cancer KEY PARA IV PRODUCTS IN THE PIPELINE (1) Therapeutic Segment / Primary Indication Anticogulant Molecule Apixaban Semaglutide pen Olaparib Diabetes 1.As of June 30, 2023 2. As of June 30, 2023. Approval received either by Natco or its marketing partner 6#7RESILIENT DOMESTIC PHARMA BUSINESS OVERVIEW OF DOMESTIC PHARMA BUSINESS Three key business segments: Oncology, Pharma specialty and Cardiology & Diabetology Focus on niche molecules with high barriers to entry. Majority of launches in India are first-time branded generics Strategic entry into high volume mass market with innovative products Promising pipeline of ~40 innovative molecules for future growth in specialty business Launched 11 products across the three business segments during FY 2022-23 DOMESTIC FORMULATION SALES(¹) (₹ IN MILLION) ONCOLOGY NATCO One of the leaders in the branded oncology medicines in India Two decades of strong presence in oncology segment with 54(¹) in 2022-23 Portfolio of well recognized brands - 6 brands with INR 100mn+ sales in the oncology segment Widened its oncology product range with introduction of additional therapy options for liver/kidney/prostrate cancers and entering into the untapped market of ovarian cancer with a novel agent PHARMA SPECIALTY 7,347 7,202 5,405 4,770 4,101 3,749 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY numbers have been prepared under Ind AS (1) Represents gross revenue 23 Brands in #1 position in indicated prescription Around 650 sales force in India 8 Brands in excess of INR 100mn+ sales 6,000+ doctors engaged through continuous professional development programmes Focus increased in areas other than Hep-C: Hep-B, Ortho-Rheuma, Critical care Market penetration into new disease areas and increased customer base translating into higher market share CARDIOLOGY & DIABETOLOGY Strengthened the portfolio with anticoagulants, anti-diabetics, anti- hypertensives, metabolic disorder therapies with novel products Apigat achieved #1 position in prescriptions with extensive market penetration and customer acquisition Fortified anti-diabetic portfolio by introducing new-age gliptins like sitagliptin Capitalised on health & nutrition awareness phenomenon with introduction of cutting-edge formulation of Vitamin D3- Nanonat D3 Expanding reach to wider base of doctors/patients/geographies through NATCO Reach by adding 250+ sales executives 7#8EXPANDING ROW PRESENCE NZ CANADA Strong portfolio with 30+ products including Oncology, anti-viral, cardiovascular and CNS therapies Amongst top 10 generic companies by sales revenue in Canada 25 approvals in place Highest market share of Nat-Lenalidomide in this molecule Launched Nat-Pomalidomide, Nat-Apixaban, Nat-Teriflunomide in the market NATCO 3,752 BRAZIL Launched Apixaban in Brazil, amongst the first to launch, through own sales and out-licensing Launched Azacitidine in Brazil through generic and brand, second generic in the market Launched Gefitinib- first to launch and the only generic Launched Vildagliptin, only generic and first-to-launch Continue to be the single source for Everolimus for the fourth consecutive year Strong market share for Oseltamivir SUBSIDIARIES REVENUE ( IN MILLION) 4,011 Launched first generic Azacitidine in the market PHILIPPINES Gaining market share in branded generics in oncology by making available basket of products at attainable prices Increasing reach in the country by selling products in additional provinces 1,086 1,085 1,814 ….... 946 FY 2018 FY 2019 FY 2020 FY 2022 FY 2023 FY 2021* Natco has 8 subsidiaries including two step-down subsidiaries ASIA-PACIFIC Participated and won large tender in Hong Kong market for Oseltamivir capsules Launched Oseltamivir capsules in China market- Natco's first product launch in the territory Won large tenders for Imatinib tablets & Erlotinib tablets in Thailand market Launched first generic Apixaban in Myanmar, Thailand & Philippines Acquired significant market share for Tenofovir Alafenamide Fumarate in Thailand, Indonesia & Vietnam markets *Includes one-time licensing fee 8#9API FACILITES NATCO Strategically important business - develops APIs primarily for third party sales and also for captive consumption Portfolio of 44 (1) active US DMFS with niche products under development Focus on complex oncology molecules. Other therapeutic areas of development includes CNS and Orphan indications Exports are focused on the US, EU, Latin America and RoW markets. In-house KSMs for several APIs a key competitive advantage MEKAGUDA TELANGANA Oncology API's and speciality products Approvals from USFDA, PMDA (Japan), COFEPRIS (Mexico), EDQM (Europe), ANVISA, WHO, EU GMP (Germany), CDSCO STRENGTHS Last USFDA audit successfully completed and EIR received in September 2019 Complex multi-step synthesis & scale-up Advanced synthetic/separation technologies Containment facility for handling High potency APIs Peptide (Solid phase) pharmaceuticals Oligo nucleotide Pharmaceuticals Well established process safety engineering lab CHENNAI TAMIL NADU Dedicated for Oncology USFDA, CDSCO, WHO-GMP USFDA audit with Establishment Inspection Report (EIR) received in July 2019 (1) As of June 30, 2023 9#10FORMULATION FACILITIES INTERNATIONAL MARKETS DOMESTIC MARKETS NATCO PHARMA LTD NATCO KOTHUR TELANGANA Oral and solid dosages including dry powder, cytotoxic & non- cytotoxic orals and cytotoxic injectables. USFDA, GMP, DCA, German Health Authority, Australia TGA, ANVISA (Brazil) USFDA audit with Establishment Inspection Report (EIR) received in August 2019 VISAKAPATNAM ANDHRA PRADESH Solid oral tablet and capsule manufacturing Site approval received from USFDA. ANVISA, Health Canada Authority Located in a Special Economic Zone (SEZ) USFDA audit with Establishment Inspection Report (EIR) received in June 2023 NAGARJUNASAGAR* GUWAHATI ASSAM TELANGANA Oncology, Antibiotics and Antiviral Tablets, Capsules ANVISA (Brazil), WHO GMP and Kenya MOH, EFMHACA- Ethiopia, NMRA- Sri Lanka, Health Canada WHO-GMP, CDSCO Compliant facility DEHRADUN UTTARAKHAND Tablets, Capsules GMP, WHO-GMP, Public Health Service of the Netherlands (EU GMP) Approvals are there to service near regulatory markets as well 10#11R&D CAPABILITIES R&D Expense (* in million) NATCO 2,500 14.0% 12% 12.0% R&D capabilities demonstrated by its complex and niche product filings in formulations and API segments 2,000 9.3% 8.7% 9.1% 7.8% 1,500 10.0% 8% 8.0% 2,267 6.0% 1,000 1,976 1,950 1,665 1,656 1,596 Two research facilities with capabilities across synthetic chemistry, nano pharmaceuticals, new drug discovery and cell biology 4.0% 500 2.0% 0.0% FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 R&D Expense R&D Expense% Specialised R&D laboratories in two research facilities Talented Pool of Scientists: 465(1) 8% 22% 70% 9% 4% 27% FINISHED DOSAGE FORMULATIONS (FDF) (2) ACTIVE PHARMACEUTICAL INGREDIENTS (API) 5% ■ AR & D ■ CR & D ■ Masters ■ Ph.D. Others 30% 25% ■ FR & D ■NDDS 19 Para IV filings in pipeline 55 Cumulative DMFs filed ■RA ■Others BREAKDOWN OF SCIENTISTS FY numbers have been prepared under Ind AS (1) As of March 31, 2023 2) As of March 31, 2023. Does not include integrated DMFS filed with ANDAS 7 approved Para IV (either tentative or final) 44 active DMFS (2 11#12CROP HEALTH SCIENCES NATCO Leveraging strong Techno-Legal expertise in Pharma to drive business in Agro-Chemical segment. Manufacturing Facilities include a Technical (Active Ingredient) and Formulation asset, located in the state of Andhra Pradesh. Operate additional leased facilities, especially to supply Granule Products. Targeting two categories of products - bioproducts and pesticides. Successfully launched broad-spectrum insecticide Chlorantraniliprole (CTPR) based products in India across key agrarian states. Launched first pheromone-based mating disruption product for management of Pink Bollworm pest for cotton Focus on registration of niche molecules, for both domestic and international markets. Technical Unit, Nellore, AP R&D Strong Chemistry team focused on development of Active Ingredient with emphasis on backward integration & cost optimization. Formulation development team with derived expertise from Pharma standards of quality and control for consistent delivery of product Target niche products post Intellectual Property (IP) assessment and Freedom to Operate boundaries PRODUCT DEVELOPMENT Field testing and wide area demonstrations of newer chemistries pan India Village adoption programs across different states for pest management Farmer training about new technologies SALES & DISTRIBUTION Sales & Marketing team comprises of over 300 direct and indirect employees Strategically picked distributors dealers across all key zones in India and Formulation Unit, Nellore, AP 12#13CONSOLIDATED FINANCIALS CONSOLIDATED PROFIT & LOSS (IN MILLION) S.No. Particulars Year ended 31 March 2023 Audited 31 March 2022 Audited 1234 Income Revenue from operations Other income Total income (1+2) Expenses Cost of materials consumed 27,071 1,046 19,448 990 28,117 20,438 4,753 5,192 Purchases of stock-in-trade 1,757 585 Changes in inventories of finished goods, work-in-progress and stock-in-trade (237) (168) Employee benefits expense (refer note 10) 4,867 4,448 Finance costs 145 177 Depreciation and amortisation expense Other expenses 1,638 1,426 6,575 6,756 Tax expense Total expenses 5 Profit/(loss) before tax for the period/ year (3-4) 6 (i) Current tax 19,498 18,416 8,619 2,022 1,627 478 (ii) Deferred tax (161) (156) Total tax expense 7 8 (i). Items that will not be reclassified to profit or loss: 1,466 322 Profit/(loss) for the period/year (5-6) Other comprehensive (loss)/ income (net of tax) 7,153 1,700 Remeasurement of defined benefit plans Net gains from investments in equity instruments designated at Fair value through other comprehensive income (FVTOCI) Income tax relating to items that will not be reclassified to profit or loss (ii). Items that will be reclassified to profit or loss: Exchange differences on translating financial statements of foreign operations Other comprehensive (loss)/ income for the period/ year, net of tax 1 Assets. (1) Non-current assets (a) Property, plant and equipment (b) Capital work-in-progress (c) Goodwill (d) Other intangible assets (e) Financial assets (i) Investments (ii) Other financial assets (f) Non-current tax assets (g) Other non-current assets Total non-current assets CONSOLIDATED PROFIT & LOSS (IN MILLION) As at 31 March 2023 (Audited) As at 31 March 2022 (Audited) NATCO 22,391 643 552 21,789 1,295 507 1,326 822 873 1,044 170 193 345 105 271 469 26,571 26,224 (2) Current assets (a) Inventories (b) Financial assets 7,429 7,620 (i) Investments 3,050 2,037 (ii) Trade receivables. 8,561 6,206 (iii) Cash and cash equivalents 1,319 1,111 (iv) Bank balances other than (iii) above 4,144 950 (v) Loans 102 104 (vi) Other financial assets 3,108 3,901 (c) Other current assets 2,290 2,938 Total current assets 30,003 24,867 Total assets 56,574 51,091 (236) ཐ བླ བླ ཁ 6 || EQUITY AND LIABILITIES 442 (1) Equity (194) (44) 404 (a) Equity share capital: 365 365 48,373 (b) Other equity Equity attributable to owners of the Company 48,738 42,271 42,636 (c) Non-controlling interest 93 Total equity 48,738 42,636 93 497 (2) Liabilities 7,180 2,197 (A) Non-current liabilities 9 Total comprehensive income/ (loss) for the period/ year (7+8) 10 Profit for the period/year attributable to: Owners of the Company 7,153 1,700 Non-controlling interests (a) Financial liabilities (ia) Lease liabilities (ii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (net) Total non-current liabilities 11 Other comprehensive income for the period/ year attributable to: Owners of the Company 27 497 Non-controlling interests (B) Current liabilities (a) Financial liabilities (i) Borrowings 12 Total comprehensive income for the period/ year attributable to: Owners of the Company 7,180 2,197 Non-controlling interests 13 Paid-up equity share capital (Face value of *2 each) 365 365 14 Other equity 48,373 42,271 (c) Provisions 15 Earnings per share (not annualised for the quarters) Total current liabilities (Face value of *2 each) Total liabilities Basic (in) 39.18 9.32 Diluted (in) 39.18 9.32 Total equity and liabilities 11 80 17 13 853 957 124 301 1,005 1,351 (ia) Lease liabilities 1,650 4,040 6 35 (ii) Trade payables total outstanding dues of micro enterprises and small enterprises; and 54 132 total outstanding dues of creditors other than micro enterprises and small enterprises 2,584 1,486 (iii) Other financial liabilities (b) Other current liabilities (d) Current tax liabilities (net) 859 833 1,408 399 169 170 101 9 6,831 7,104 7,836 8,455 56,574 51,091 13#14QUARTERLY FINANCIAL SUMMARY NATCO Revenue Division SEGMENTAL BREAKDOWN (IN MILLION) Q1FY24 Q1FY23 CONSOLIDATED FINANCIAL RESULTS (IN MILLION) FY 23 FY22 A) API Revenue(¹):- 751 508 2,103 2,481 Total Revenues Q1FY24 Q1FY23 11,602 9,189 28,117 20,438 FY 23 FY22 B) Formulation:- EBITDA 5,477 4,296 10,402 3,625 B1) Formulation - Exports (incl profit share, license income, export service income & Subsidiaries) 8,842 7,369 20,632 11,842 EBITDA Margin (%) 47.2% 46.8% 37.0% 17.7% B2) Formulation - Domestic 1,324 885 3,749 4,771 Profit for the period (PAT) 4,203 3,204 7,153 1,700 Formulations Total Revenue (B1+B2) 10,166 8,254 24,381 16,612 PAT Margin (%) 36.2% 34.9% 25.4% 8.3% C) Crop Health Sciences 447 10 409 51 D) Other Operating & Non - operating incomes 238 417 1,224 1,293 Consolidated Total Revenue 11,602 9,189 28,117 20,438 14#15OPEN 20.12 IG 250mil 10.12 250m Όταν BOROSU 100 NATCO Email: [email protected] Phone: 040-2354 7532